Insight into *Acinetobacter baumannii*: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities

Muhammad Asif^{1,2}
Iqbal Ahmad Alvi^{1,3}
Shafiq Ur Rehman¹

¹Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan; ²Department of Pathology, King Edward Medical University, Lahore, Pakistan; ³Department of Microbiology, Hazara University, Mansehra, Pakistan

Abstract: *Acinetobacter baumannii*, once considered a low-category pathogen, has emerged as an obstinate infectious agent. The scientific community is paying more attention to this pathogen due to its stubbornness to last resort antimicrobials, including carbapenems, colistin, and tigecycline, its high prevalence of infections in the hospital setting, and significantly increased rate of community-acquired infections by this organism over the past decade. It has given the fear of pre-antibiotic era to the world. To further enhance our understanding about this pathogen, in this review, we discuss its taxonomy, pathogenesis, current treatment options, global resistance rates, mechanisms of its resistance against various groups of antimicrobials, and future therapeutics.

Keywords: antibiotic resistance, colistin, tigecycline, phage therapy

Introduction

Acinetobacter baumannii, a non-fermenter Gram-negative coccobacillus, was considered a low-category pathogen in the past, but has now emerged as a leading cause of hospital- and community-acquired infections. It is a frequent cause of pneumonia and septicemia in immunocompromised patients. It resists many classes of antibiotics by virtue of chromosome-mediated genetic elements on one hand, while it can also persist for a prolonged period in harsh environments (walls, surfaces, and medical devices) in the hospital settings on the other hand.^{1,2}

A. baumannii was isolated for the first time from soil by a Dutch bacteriologist Beijerinck in 1911 and was described as *Micrococcus calcoaceticus*.³ In succeeding 50 years, the same bacterium was isolated many times and reported with different names such as *Moraxella lwoffii*, *Alcaligenes hemolysans*, *Mirococcus calco-aceticus*, and *Herellea vaginicola*. Four decades later, Brisou and Prevot purposed to include it in the genus *Achromobacter*, based on its inability to move and being non-pigmented.⁴ In 1968, Baumann et al placed all such isolates in one genus *Acinetobacter*, which was accepted by the committee on the taxonomy of Moraxella and Allied Bacteria 4 years later.⁵ Based on DNA similarity, Bouvet and Grimont further classified it into 12 groups in 1986.⁶ Currently, they are taxonomically classified as γ -proteobacteria, family Moraxellaceae and order Pseudomonadales.⁷

Acinetobacter calcoaceticus-baumannii complex is a group of aerobic, non-fermentative, gram-negative coccobacillus that encompasses four different *Acinetobacter* species, comprising *A. baumannii*, *Acinetobacter pittii*, *Acinetobacter nosocomialis*, and *Acinetobacter calcoaceticus*. The first three are implicated in infections, while the latter is rarely considered pathogenic.⁸ It appears as Gram-negative coccobacillus

Correspondence: Shafiq Ur Rehman
Department of Microbiology and Molecular Genetics, University of the Punjab, New Campus, Canal Bank Road
PO Box No. 54590, Lahore, Punjab, Pakistan
Tel +92 321 490 5423
Email shafiq.mmg@pu.edu.pk

in pairs ranging from 1 to 1.5 μm when observed under the microscope after gram staining. It often resists complete decolorization and can deceive as Gram-positive cocci. Nutritionally, it is aerobic, non-fastidious, and a non-fermenter. It is a non-motile organism and does not produce cytochrome oxidase, urease, citrate, and indole; however, it produces catalase enzyme. *A. calcoaceticus-baumannii* complex nurtures well at 35°C–37°C; however, some environmental isolates grow well in the temperature range of 20°C–30°C. *A. baumannii* is the only bacterium in the genus that can grow at 44°C.⁶

It grows well on routine laboratory media such as blood agar, chocolate agar, and MacConkey agar. On blood agar, it forms colorless, non-hemolytic, shiny mucoid colonies, smooth in contexture with a diameter of 1–2 mm after 18–24 hours of incubation at 37°C. It produces colorless colonies on MacConkey agar which are shiny mucoid and tomb shaped, indicating its non-lactose fermenting ability. On selective agar, Leeds *Acinetobacter* Medium, it gives pink color colonies when grown in the presence of supplement.⁹

Acinetobacter spp. are free-living saprophytic organisms and widely distributed in different environments including soil, water, wastewater, vegetables, and skin of animals and humans.¹⁰ They have been isolated from various body parts of healthy individuals, including the nose, ear, throat, forehead, trachea, conjunctiva, vagina and perineum, axillae, groin, hands, and toe webs; however, most strains isolated were other than *A. baumannii*.¹¹ In hospital environment, they reside on beds, curtains, walls, roofs, medical devices, and equipment, as well as on belongings of medical personnel, tap water sinks, telephones, door handles, hand sanitizers, dispensers, trolleys, bins, and even on computers. They have the capacity to survive for prolonged periods on inanimate objects. The factors that are responsible for their persistence in a hospital environment are resistance to key antimicrobial drugs and disinfectants and their ability to survive in desiccants.¹²

Pathogenicity of *A. baumannii*

A. baumannii has emerged as a major culprit involved in causing nosocomial infections, especially in intensive care units (ICUs) worldwide. The capability of this organism to pollute hospital surfaces for extended periods is linked with nosocomial outbreaks.¹³ It has gained the ability to infect not only hospitalized patients but also the general population. In hospital settings, it confers 26% mortality rate that goes up to 43% in ICUs.¹⁴ *A. baumannii* is a principal agent of ventilator-associated pneumonia, which accounts for nearly 15% of all hospital-acquired infections, with the highest

morbidity and mortality in medical wards and especially in the ICUs. It accounts for ~50% of the total use of antibiotics in the ICUs.¹⁵

A. baumannii is not considered a community pathogen, but in immunocompromised individuals and in children, it populates tracheostomy sites and can cause community-acquired bronchiolitis and tracheobronchitis. It has also been implicated in community-acquired pneumonia with underlying conditions such as smoking, alcoholism, diabetes mellitus, and COPD in tropical regions of Asia and Australia.¹⁶ *A. baumannii* has been implicated in bloodstream infections in 10%–15% of cases due to invasive procedures (intravascular or respiratory catheters, tubes, or cannulas). In 20%–70% of *A. baumannii* infections, the origin of infection remains unknown.¹⁷

A. baumannii is an increasing threat to neurosurgery patients. It is responsible for 4% of all meningitis and shunt-related infections, with 70% mortality rates.¹⁸ It is responsible for 2.1% of ICU-acquired wound infections; however, its prevalence is more pronounced (32%) in casualties from battlefields of Afghanistan and Iraq. It is not a usual agent of urinary tract infections (UTIs); however, it can cause infection in debilitated elderly patients and in patients with prolonged indwelling catheter-related infections in the ICUs where it contributes 1.6% of the total UTIs. It may cause endocarditis, keratitis, and ophthalmitis following use of the contact lens and eye surgery.¹⁹

A. baumannii can be transmitted through the vicinity of affected patients or colonizers such as linens fomites, curtains, bed rails, tables, sinks, doors, feeding tubes, and even medical equipment. Contamination of respiratory support equipment, suction devices, and devices used for intravascular access is the key source of infection.²⁰

A. baumannii is considered as a low-virulence pathogen, unless it is isolated from patients having comorbidities such as neonates with low birth weights and elderly patients with chronic illnesses such as malignancy. Major predisposing factors important in the acquisition of *A. baumannii* infection include prolonged hospital stay, mechanical ventilation, intravascular device, advanced age, immunosuppression, previous broad-spectrum antimicrobial therapy, previous sepsis, ICU stay, and enteral feedings.²¹

Pathogenesis of *A. baumannii*

The intrusion of a microorganism requires cell-to-cell adhesion to establish infection; however, the capability of *A. baumannii* to anchor with cells/mucosal cells is low as compared to other microorganisms such as *Pseudomonas*

aeruginosa, *Neisseria meningitidis*, *Campylobacter*, *Yersinia enterocolitica*, and *Helicobacter pylori*.²² The reduced adhesion and invasion of *A. baumannii* attribute to its low virulence; however, it possesses a hydrophobic ability that provides attachment to foreign materials such as plastics used in intravascular devices. It has been proven that surface hydrophobicity is highly expressed in strains isolated from patients as compared to normal flora of the skin.¹⁹

Outer membrane protein A (OmpA) is associated with improving adhesion, specifically to the epithelial cells of the respiratory tract. It localizes in the mitochondria and nuclei and induces expression of proapoptotic molecule cytochrome *c*, resulting in cell death.²³ *A. baumannii* evades alternative complement pathway-mediated killing by neutralizing factor H, a key regulator of alternative complement pathway, with the help of OmpA. This phenomenon is known as serum resistance of *A. baumannii*.²⁴ OmpA induces differentiation of CD4⁺, activation and maturation of dendritic cells, and causes their premature apoptosis.²⁵

Secretion of outer membrane vesicles that contain different virulence-related proteins (proteases, phospholipases, superoxide dismutase, and catalase) at the infection site accelerates the local innate immune response and ultimately leads to tissue damage. The outer membrane vesicles also augment biofilm formation on abiotic surfaces.²⁶ Polysaccharide capsule of Gram-negative rods is notorious as a virulence factor. It plays a central role in guarding bacteria against phagocytosis by the host innate immune system.²⁷ Lipopolysaccharides (LPSs) of *A. baumannii* consist of an O-antigen, the carbohydrate core, and a lipid A moiety. LPS is a chemotactic agent that recruits inflammatory cells and compels them to release their cytotoxic material.²⁸

Quorum sensing is the capability of bacteria to communicate with their neighboring counterparts to respond jointly to the changing environment. They produce small easily diffusible hormone-like molecules known as autoinducers, which are used to observe their population density and to adapt in an ever-changing environment.²⁹ Like other Gram-negative rods, *Acinetobacter* yields acylhomoserine lactones as signaling molecules for interspecies and intraspecies communication. It also produces less-studied signaling molecules such as diketopiperazines, 2-heptyl-3-hydroxy-4-quinolone, and retention factor 1.³⁰

Despite the abundance of iron in biological systems, availability of biologically active ferric iron is relatively low due to its decreased solubility in an aerobic environment and chelation by other compounds such as hemoglobin and ferric-binding protein called transferrin.³¹ *A. baumannii* is unable

to acquire iron from transferrin or lactoferrin; however, it possesses siderophores, which have iron acquisition ability devoted to iron accumulation from heme.³²

The ability of *A. baumannii* to form biofilms on biotic and abiotic surfaces is a well-studied mechanism of resistance. To survive in unfavorable conditions, it becomes metabolically inert in the deeper layers of biofilms. Poor penetration and the inability of antibiotics to act on metabolically inert bacteria augment its virulence.¹⁴ *A. baumannii* involved in epidemics shows a high-level desiccation resistance and biofilm-forming capability on biological surfaces. The property of *A. baumannii* to form pellicle by virtue of polysaccharide, poly-*N*-acetyl glucosamine, and csuA/B usher protein is a way to offshore antibiotic effect. Other virulence factors are also involved in biofilm evolution, including biofilm-associated protein (BAP), OmpA, BAP-like protein-1 (BLP-1), and BAP-like protein-2 (BLP-2).³³

Antibiotic resistance and treatment options against *A. baumannii*

Discovery of antibiotics was a remarkable milestone in the history of modern medicine. The discovery of penicillin, followed by sulfonamides and aminoglycosides, urged scientists to speculate that a “magic bullet” to wipe out the infectious diseases has been found. However, unfortunately, the scenario is not as true as once thought. Fleming stated in his Nobel lecture that, in future, antibiotics will be easily available to everyone and quacks might undermine the positive role of antibiotics through exposing a persistent low regimen to bacteria that can result in the evolution of antibiotic resistance.³⁴

Penicillin was administered for the first time in 1941, and penicillin-resistant isolates were detected in 1942. Similarly, methicillin was introduced in 1960 and methicillin-resistant strains were reported in 1961 and so on.³⁵ Currently, the isolates of *A. baumannii* resistant to all available antimicrobials have been reported.³⁶ The hard work of scientific community resulted in discovery of many antibiotics, but their misuse resulted in high degree of resistance. It can be said that pre-antibiotic era has started, where again microbes with greater killing capacity are in abundance.³⁷ *Acinetobacter* has been endowed with the genetic setup for rapid development of antimicrobial resistance, and therefore, is known as a natural transformant. Scientific literature is full of reports stating it as one of the toughest bacteria.³⁸

Until early 1970s, *Acinetobacter* infections were treatable with ampicillin, carbenicillin, gentamicin, and nalidixic acid, either as a monotherapy or combination therapy, but high rates of resistance were noticed after 1975.³⁹ Presently, many

valuable drugs such as ureidopenicillin, aminopenicillins, narrow-spectrum and even extended-spectrum cephalosporin, tetracycline, chloramphenicol, cephamycins such as cefoxitin, and most aminoglycosides have lost their efficacy against *Acinetobacter*.⁴⁰

Carbapenems (imipenem and meropenem), aminoglycosides (amikacin and tobramycin), fluoroquinolones (ciprofloxacin and levofloxacin), broad-spectrum cephalosporins (ceftazidime, cefotaxime, ceftriaxone, cefepime), and combinations of beta-lactamase inhibitors with antibiotic (ampicillin/sulbactam) are currently being used, provided that the organisms are susceptible; however, the minimum inhibitory concentrations (MICs) have substantially increased.¹

Carbapenems

Carbapenems have been the mainstay of antimicrobial therapy against *A. baumannii* infections since 1990. Overwhelming resistance to carbapenems was first reported in 1985, the year of imipenem discovery, declaring that antibiotic resistance mechanisms existed even before their first use. Currently, about 8%–26% isolates are susceptible to imipenem, depending on the region of the world.⁴¹ North America and Europe harbor 13%–15% of carbapenem-resistant *Acinetobacter*; in comparison to Latin America, where 40% resistance has been reported.⁴² Another study reported 48% carbapenem resistance in the USA.⁴³ Alarmingly, a recent review mentioned 50%, 85%, and 62%–100% as the frequency of carbapenem-resistant *Acinetobacter* in Singapore, India, and Pakistan, respectively. Likewise, the frequency of carbapenem-resistant *A. baumannii* was reported to be 70%, 92%, and 100% in Chile, Korea, and Portugal, respectively. The resistance to carbapenems also renders other beta-lactam drugs ineffective.⁴⁴ Worse clinical outcomes with carbapenem-resistant *Acinetobacter* infections have been reported by many authors.⁴⁴

Colistin

Colistin or polymyxin E is a bactericidal drug that disrupts cell membrane like a detergent. Its positively charged cationic region binds to negatively charged hydrophilic portion of LPSs. The resulting loss of integrity causes cell death.⁴⁵ The current panic situation of antibiotic resistance in *Acinetobacter* infections had led to the use of historically discarded drug, colistin. Colistin has shown high nephrotoxicity, ranging from 11% to 76% in various retrospective and prospective studies. Therefore, its use was discontinued short after its discovery in late 1950s. However, recent studies do not advocate such higher incidence of nephrotoxicity

in comparison to previous studies, if associated risk factors are kept in mind, such as dose, age of patient, duration, and existing comorbidities such as hypertension, obesity, and hypoalbuminemia.^{46,47} The mechanisms of colistin-induced nephropathy are not clearly understood; however, certain studies in this field suggested that accumulation of colistin in proximal renal tubules results in oxidative damage. Caspase-mediated apoptosis, inducible nitrous oxide synthase, and endothelial nitrous oxide synthase are also implicated in pathogenesis of nephrotoxicity.⁴⁸ Colistin-driven neurotoxicity is infrequent and includes bronchoconstriction, cough, and chest tightness when administered via respiratory tract and results in chemical meningitis.^{49,50} Other dose-dependent reversible adverse effects include ataxia, apnea, paresthesias, delirium, visual disturbances, seizures, vertigo, and neuromuscular defects.⁵¹

Colistin is administered as a pro-drug in the form of colistin methanesulfonate; so, achievement of its critical levels in blood is difficult. Therefore, its use as monotherapy results in rapid emergence of regrowth. Heteroresistance (selective resistance of bacterial subpopulation followed by amplification) is another phenomenon that results in rapid emergence of resistant clones.^{52,53}

Low plasma levels and heteroresistance of colistin raised serious concern on colistin monotherapy.⁵⁴ Combination of colistin with other in vitro active agents that gives a synergistic effect is widely used by physicians in critically ill patients. However, debate is still open in literature about the advantages of combination versus monotherapy. Some studies suggest monotherapy as effective as combination.^{55,56} Extensive review of literature favored combination therapy in terms of microbiological clearance as well as clinical cure in *A. baumannii* infections.^{57,58} Colistin/carbapenem and colistin/rifampicin are the most studied combinations that have well-established in vitro and in vivo activities, and also, proved to be effective in the clinics.^{59,60} Other studied combinations include colistin/tigecycline, colistin/minocycline, colistin/aminoglycosides, colistin/ampicillin–sulbactam, colistin/trimethoprim–sulfamethoxazole, colistin/fosfomycin, colistin/daptomycin, and colistin/sulbactam.^{61–64}

Unfortunately, resistance has emerged against this last resort antibiotic. Colistin-resistant *Acinetobacter* was first reported in the Czech Republic in 1999.⁶⁵ Now it is increasingly being reported worldwide.⁶⁶ Low levels of resistance (2.1%–7.1%) have been reported from the USA, while reports from Europe have documented 7%–11% resistance. Highest resistance has been reported from India (53%), followed by

Iran (48%), Spain (40.7%), and Korea (30%)^{57,67} as shown in Table 1.

Tigecycline

Tigecycline, being the first member of glycylglycyl, is a novel drug approved by the US Food and Drug Administration in June 2005 for the treatment of complicated skin infections, community-acquired pneumonia, and intra-abdominal infections.⁶⁸ It is also being used in the treatment of bacteremia and UTIs by multidrug-resistant (MDR) Gram-negative bacteria.⁶⁹ It is active against a wide number of Gram-positive and Gram-negative bacteria including anaerobes.⁷⁰ It has shown effectiveness against *A. baumannii* and other species of *Acinetobacter* in large number of studies.⁷¹

Testing the sensitivity of *A. baumannii* to tigecycline is not standardized yet. The European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute still do not have established breakpoints for tigecycline sensitivity testing. However, many researchers use more flexible breakpoints, as reported by the US Food and Drug Administration (sensitive: ≤ 2 mg/L, resistant ≥ 8 mg/L).⁷² Therefore, interpretation of antimicrobial sensitivity in many studies has been controversial. The method of MIC determination also affects the results: E test gives somewhat higher MIC value than broth dilution method.⁷³ The determination of MIC by Vitek 2 is reliable in 94% cases.⁷⁴

The first case of tigecycline resistance was reported by Sader et al in 2005 and in 2007 Navon-Venezia et al reported 66% tigecycline resistance against *A. baumannii* in Israel.^{75,76} At times, varying percentages of resistance have been reported all over the world, with Turkey possessing the highest resistance rate (81%), as shown in Table 2.

Mechanism of resistance

Enzyme-mediated degradation (beta-lactamases), genetic manipulations (mutations, acquiring or leaving a gene, upregulation or downregulation of gene expression), and efflux pumps are different strategies adopted by *Acinetobacter* to escape from destruction of antibiotics.⁷⁷

Resistance to beta-lactams

Resistance to beta-lactam antibiotics is mediated through enhanced degradation by beta-lactamases, alteration in penicillin-binding proteins, changes in outer membrane porins for decreased permeability, and expulsion of antibiotics out of cell through efflux pump (Figure 1-I).⁷⁸ Among beta-lactamases, ampC cephalosporinase or molecular class c beta-lactamase is more prevalent in *A. baumannii*.⁷⁹ It is encoded by *bla* gene and confers resistance to penicillins and narrow- and extended-spectrum cephalosporins. Other beta-lactamases include class A beta-lactamases such as extended-spectrum beta-lactamases (PER-1, VEB-

Table 1 Studies showing colistin resistance by *Acinetobacter* in different regions of the world

Author	Year	% Colistin resistance (resistant isolate/total)	Region	Reference
Bashir et al	2014	1 (1/100)	Pakistan	104
Qadeer et al	2016	3	Pakistan	105
Gupta et al	2016	53.1 (17/32)	India	106
Pawar et al	2016	11.9 (42/359)	India	107
Am et al	2016	4.2 (45/47)	India	108
Samawi et al	2016	1.4 (2/137)	Qatar	109
Maraki et al	2016	7.9 (15/189)	Greece	110
Al-Samaree et al	2016	20 (10/50)	Iraq	111
Alaei et al	2016	16 (14/85)	Iran	112
El-Shazly et al	2015	4.7 (1/21)	USA	113
Maspi et al	2016	48.8 (42/86)	Iran	114
Ambrosi et al		3.2 (1/31)	Italy	115
Chang et al	2012	10.4 (14/134)	Taiwan	116
Rossi et al	2016	1.4 (102/7446)	Brazil	117
Batarseh et al	2015	1.8(2/116)	Jordan	118
Qureshi et al	2015	20 cases	USA	119
Tojo et al	2015	1 case	Japan	120
Daadani et al	2013	1.8 (24/1307)	Saudi Arabia	121
Cikman et al	2015	2.5 (1/40)	Turkey	122
Castanheira et al	2014	1.2 (65/5477)	USA	123
Al-Sweih et al	2011	12 (30/250)	Kuwait	124
Ghasemian et al	2016	8 (4/50)	Iran	125

Table 2 Studies showing tigecycline resistance by *Acinetobacter* in different regions of the world

Author	Year	% Tigecycline resistance (resistant isolate/total)	Region	Reference
Kulah et al	2009	14.3	Turkey	126
Liao et al	2008	19.1	Taiwan	127
Dizbay et al	2008	47	Turkey	128
Behera et al	2009	57.6	India	129
Chang et al	2012	45.5	Taiwan	116
Kim et al	2010	23.4	Korea	130
Al-Sweih et al	2011	13.6	Kuwait	124
Van et al	2014	41.3	Vietnam	131
Baadani et al	2013	9.7	Saudi Arabia	121
Garza-Gonzalez et al	2010	3	Mexico	132
Garcia et al	2009	20	Chile	133
Rizek et al	2015	0	Brazil	134
Ahmed et al	2012	24	South Africa	135
Capone et al	2008	27.5	Italy	136
Mendes et al	2010	3	Worldwide	137
Dizbat et al	2008	25.8	Turkey	138
Farrell et al	2010	0.2 (1/397)	Asia-Western Pacific	139
Bahador et al	2013	20	Iran	140
Hasan et al	2014	20	Pakistan	141
Al-Agamy et al	2016	56	Saudi Arabia	142
Chmielar et al	2016	18.4 (23/125)	Poland	143
Tsioutis et al	2016	74.2	Greece	144

1, CTX-M, TEM, SHV), class B beta-lactamases such as metallo-beta-lactamases (MBLs; IMP, SIM, VIM), and class D beta-lactamases such as OXA.⁸⁰ Acquired OXA-type carbapenemases are the mainstay against carbapenems, a treatment of choice, followed by MBLs.⁸¹ OXA23, OXA24, and OXA58 are plasmids that encode carbapenemases which are mainly responsible for carbapenem degradation. Coexistence of OXA23 and an MBL NDM-1, a nightmare in the history of antibiotic resistance, has been reported.⁸² All other types of OXA are chromosome mediated and include OXA25, OXA26, and OXA40.

Reduced entry of drugs via outer membrane proteins (OMPs) or porins and modification of penicillin-binding proteins (PBPs) are implicated in resistance to beta-lactams. Many studies suggested reduced expression of OMPs and PBP2 results in carbapenem resistance. Among OMPs, a 43 kDa protein oprD and a 29 kDa protein CarO are the most studied porins that support the hypothesis of decreased expression. Probably, porins and beta-lactamase work collectively in conferring resistance.⁸³

Presence of efflux pumps confers resistance to multiple classes of antibiotics. Six families of efflux pumps have been identified which include resistance nodulation cell division family, small multidrug resistance superfamily, ATP-binding cassette (ABC) family, major facilitator superfamily, multidrug toxic compound extrusion family,

and recently identified proteobacterial antimicrobial compound efflux family.⁸⁴ AdeABC efflux pump has been well characterized in *A. baumannii* and is a member of resistance nodulation cell division family that mediates resistance to many classes of antibiotics (cefotaxime, chloramphenicol, erythromycin, aminoglycosides, and fluoroquinolones). Overexpression of AdeABC also confers resistance to carbapenems.⁸⁵ AbeS, a member of small MDR efflux pump, has also been identified in *A. baumannii*.⁸⁶ AdeABC, AdeIJK, and AdeFGH are the major drug efflux pumps of ABC family. Other members of major facilitator superfamily include CraA, AmvA/AedF, and Tet(B). Members of recently discovered proteobacterial antimicrobial compound efflux family include AceI, while a representative of multidrug toxic compound extrusion family includes AbeM pump.⁸⁷

Resistance to aminoglycoside

The most frequent mechanism of aminoglycoside resistance is the modification of amino or hydroxyl group by aminoglycoside modifying enzymes. All types of aminoglycoside modifying enzymes (adenylases, acetylases, methyltransferases, and phosphotransferases) have been identified in *Acinetobacter*. Reduced drug entry and alteration in target ribosomal protein are the other mechanisms involved in aminoglycoside resistance (Figure 1-II).⁸⁸

Figure 1 Different mechanisms of resistance in *A. baumannii*: (I) beta-lactams; (II) aminoglycosides; (III) quinolones; (IV) colistin.

Abbreviations: AME, aminoglycoside modifying enzyme; LPS, lipopolysaccharide; OMP, outer membrane porin; PBP, penicillin-binding protein.

Resistance to quinolones

Major mechanism for resistance to quinolones is mutations in the *gyrA* and *parC* genes, which results in phenotypic changes in DNA gyrase and topoisomerase IV, leading to reduced drug affinity.⁸⁹ Drug influx and efflux system encoded by chromosomal DNA mediates reduced expression of OMPs involved in drug influx and increased expression of efflux proteins resulting in active drug expulsion; these are also responsible for quinolone resistance.⁹⁰ Plasmid-encoded quinolone resistance determinants *qnrA*, *qnrB*, and *qnrS* have also been identified in *A. baumannii* that protect DNA by inhibiting binding of quinolones to DNA gyrase and topoisomerase (Figure 1-III).^{91,92}

Mechanism of colistin resistance

The mechanisms of resistance to colistin are encoded by chromosomal DNA of the bacteria. Two major mechanisms have been reported. The first mechanism consists of mutations in lipid A encoding genes (*lpxA*, *lpxC*, and *lpxD*), resulting in loss of LPS, an outer part of Gram-negative organisms and an initial target of colistin.⁹³ The second mechanism involves the two-component system of pmrAB, which is a response regulator and sensor kinase. It senses the environmental conditions (pH, Mg^{2+} , and Fe^{3+}) and, in response, regulates the expression of genes involved in lipid A synthesis. Point mutations

in *pmrA* and *pmrB* upregulate their gene expression, resulting in remodeling of outer membrane (Figure 1-IV).⁹⁴ Recently, a plasmid-mediated colistin resistance gene, *mcr-1*, has been reported in *Escherichia coli*.^{95,96} Although *mcr-1* gene has not been identified in *A. baumannii*, still it is speculated that progression from MDR *Acinetobacter* to pan drug resistance is unavoidable due to the arrival of transmissible colistin resistance mechanisms.⁹⁷

Alternate modalities

The dilemma of rapidly increasing antibiotic resistance with minimal options left in hand has steered the scientific community to think beyond antibiotics. In the last decade, renaissance of research in the field of different alternatives to antibiotics has intensified. Previously neglected modalities with therapeutic potential against MDR bacteria cannot be left apart. Bacteriophages are the best example of neglected modality. Bacteriophages and their encoded products such as lysins are extensively being studied as an alternative to antibiotics. The wild-type bacteriophages and their enzymatic products act in a manner like antibiotics and destroy target bacteria. The first report of isolation and characterization of phages against *A. baumannii* was published in 2010. The phages AB1 and AB2 have specifically shown lytic behavior against *A. baumannii*. Since then,

many lytic phages have been isolated, characterized, and sequenced. The bulk of in vitro studies and characterization of phages against *A. baumannii* urged a dire need to test their in vivo efficacy and pharmacodynamics to fight back infectious diseases.^{98,99}

Monoclonal antibodies are one alternative that can be used to treat *A. baumannii* infections. They bind to virulence factors of pathogens and neutralize them. It seems prudent to use them as an alternative due to their well-studied phenomena and clinical outcomes. However, their production is too expensive to be used for treating infections. Probiotics are live bacteria that exert a healthy effect on humans. They act by competing for the pathogen in the acquisition of nutrition and space for colonization; however, their exact mechanism of action is under study.¹⁰⁰

Antimicrobial peptides (AMPs) or short AMPs are produced by various eukaryotic and prokaryotic organisms as their part of innate host immune response. They hold the potential to kill bacteria, so interest in AMPs as an alternative to antibiotic is increasing day by day. They are broad spectrum in nature, have low immunogenicity, low resistance, and carry a solution of antibiotic resistance for Gram-positive as well as Gram-negative bacteria. Several peptides having in vitro and in vivo activities against *A. baumannii* have been reported. A hybrid of cecropin A and melittin has shown activity in peritoneal sepsis by pan drug-resistant strain of *A. baumannii* in an animal model of infection. Brevinin 2, alyteserin 2, and cationic α -helical peptides have also demonstrated bactericidal activity against *A. baumannii*. A proline-rich peptide A3-APO has exhibited greater efficacy in controlling *A. baumannii* bacteremia in comparison to imipenem in a mice model. A short D-enantiomeric peptide D-RR4 protected the *Caenorhabditis elegans* model of infection from lethal infection by *A. baumannii*. Many successful reports exist in literature about potential of AMPs against such a robust organism, but factors such as cytotoxicity, moderate activity, enzymatic degradation, and high productivity cost need to be evaluated prior to concluding about their systemic use as an antibiotic.^{100,101}

Gene editing technique by using clustered, regularly interspaced short palindromic repeat (Cas) system to knock out the resistance gene and make it labile to antimicrobial therapy is another possible way to nib such bugs.

Metal chelators that are essential in the expression of bacterial virulence factors, such as iron, zinc, and manganese, can be a promising target for designing newer antimicrobial drugs. Artificial nanoparticles made of lipids known as “liposomes” that closely resemble the membrane of host cells can

act as decoys for bacterial toxins, and so are able to sequester and neutralize them.^{102,103}

Conclusion

A. baumannii has emerged as an established nosocomial pathogen and exhibits a higher level of resistance to many antibiotics. Extensively drug resistant and pan drug resistant isolates are routinely being reported in various medical facilities. Carbapenems, the drug of choice to treat *A. baumannii* infections, are increasingly being ineffective due to higher resistance rates. Even resistance to newer antimicrobial tigecycline is emerging rapidly. Historically discarded drug colistin is left as the last resort antimicrobial, but resistance against this drug is also being reported all over the world at higher rates. Such vanishing treatment options have steered up the scientific community to look for an alternative to antibiotics. These alternatives are the dire need of the time and hopefully will be available in future.

Author contributions

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Pourhajibagher M, Hashemi FB, Pourakbari B, Aziemzadeh M, Bahador A. Antimicrobial resistance of *Acinetobacter baumannii* to imipenem in Iran: a systematic review and meta-analysis. *Open Microbiol J*. 2016;10:32–42.
2. Qi L, Li H, Zhang C, et al. Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in *Acinetobacter baumannii*. *Front Microbiol*. 2016;7:483.
3. Beijerinck M. Pigmenten als oxydatieproducten gevormd door bacterien. *Versl Koninklijke Akad Wetensch Amsterdam*. 1911;19:1092–1103.
4. Brisou J, Prevot AR. Studies on bacterial taxonomy. X. The revision of species under *Acromobacter* group. *Annales de l'Institut Pasteur*. 1954;86(6):722–728.
5. Baumann P. Isolation of *Acinetobacter* from soil and water. *J Bacteriol*. 1968;96(1):39–42.
6. Bouvet PJ, Grimont PA. Identification and biotyping of clinical isolates of *Acinetobacter*. *Annales de l'Institut Pasteur/Microbiologie*. 1987;138(5):569–578.
7. Nemec A, Radolfova-Krizova L, Maixnerova M, Vrestiakova E, Jezek P, Sedo O. Taxonomy of haemolytic and/or proteolytic strains of the genus *Acinetobacter* with the proposals of *Acinetobacter courvalinii* sp. nov.(genomic species 14 sensu Bouvet & Jeanjean), *Acinetobacter dispersus* sp. nov.(genomic species 17), *Acinetobacter modestus* sp. nov., *Acinetobacter proteolyticus* sp. nov. and *Acinetobacter vivianii* sp. nov. *Int J Syst Evol Microbiol*. 2016;66(4):1673–1685.
8. Pourabbas B, Firouzi R, Pouladfar G. Characterization of carbapenem-resistant *Acinetobacter calcoaceticus-baumannii* complex isolates from nosocomial bloodstream infections in southern Iran. *J Med Microbiol*. 2016;65(3):235–239.

9. Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. *Saudi J Biol Sci*. 2018;25(3):586–596.
10. Maravić A, Skočibušić M, Fredotović Ž, et al. Urban riverine environment is a source of multidrug-resistant and ESBL-producing clinically important Acinetobacter spp. *Environ Sci Pollut Res Int*. 2016;23(4):3525–3535.
11. Al Atrouni A, Joly-Guillou M-L, Hamze M, Kempf M. Reservoirs of non-baumannii acinetobacter species. *Front Microbiol*. 2016;7:49.
12. Evans BA, Hamouda A, Amyes SG. The rise of carbapenem-resistant Acinetobacter baumannii. *Curr Pharm Des*. 2013;19(2):223–238.
13. Shimose LA, Masuda E, Sfeir M, et al. Carbapenem-resistant Acinetobacter baumannii: concomitant contamination of air and environmental surfaces. *Infect Control Hosp Epidemiol*. 2016;37(7):777–781.
14. Greene C, Vadlamudi G, Newton D, Foxman B, Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. *Am J Infect Control*. 2016;44(5):e65–e71.
15. Demirdal T, Sari US, Nemli SA. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? *Ann Clin Microbiol Antimicrob*. 2016;15(1):1–6.
16. Silva GM, Morais L, Marques L, Senra V. Pneumonia adquirida na comunidade numa criança saudável por Acinetobacter. *Revista Portuguesa de Pneumologia*. 2012;18(2):96–98.
17. Garnacho-Montero J, Amaya-Villar R, Ferrándiz-Millón C, Díaz-Martín A, López-Sánchez JM, Gutiérrez-Pizarra A. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia. *Expert Rev Anti Infect Ther*. 2015;13(6):769–777.
18. Basri R, Zueter AR, Mohamed Z, et al. Burden of bacterial meningitis: a retrospective review on laboratory parameters and factors associated with death in meningitis, Kelantan Malaysia. *Nagoya J Med Sci*. 2015;77(1–2):59.
19. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. *Clin Microbiol Rev*. 2008;21(3):538–582.
20. Jung J, Park W. Acinetobacter species as model microorganisms in environmental microbiology: current state and perspectives. *Appl Microbiol Biotechnol*. 2015;99(6):2533–2548.
21. Islahi S, Ahmad F, Khare V, Yaqoob S, Shukla P, Singh Y. Incidence and risk factors associated with Acinetobacter species infection in hospitalised patients in a tertiary care hospital in North-India. *J Comm Dis*. 2015;46(3):10–12.
22. Tibor P, Tudományegyetem P. *Molecular epidemiological studies on sporadic and epidemic isolates of Acinetobacter baumannii* [doctoral thesis]. Hungary: University of Pécs; 2013.
23. Schweppe Devin K, Harding C, Chavez Juan D, et al. Host-microbe protein interactions during bacterial infection. *Chem Biol*. 2015;22(11):1521–1530.
24. Kim SW, Oh MH, Jun SH, et al. Outer membrane protein A plays a role in pathogenesis of acinetobacter nosocomialis. *Virulence*. 2016;7(14):413–426.
25. Lee JS, Choi CH, Kim JW, Lee JC. Acinetobacter baumannii outer membrane protein A induces dendritic cell death through mitochondrial targeting. *J Microbiol*. 2010;48(3):387–392.
26. Nho JS, Jun SH, Oh MH, et al. Acinetobacter nosocomialis secretes outer membrane vesicles that induce epithelial cell death and host inflammatory responses. *Microb Pathog*. 2015;81:39–45.
27. Barrie A, Gorman M. Acinetobacter baumannii—The New MRSA? *Eplasty*. 2016;16.
28. Rossi E, Longo F, Barbagallo M, et al. Glucose availability enhances lipopolysaccharide production and immunogenicity in the opportunistic pathogen Acinetobacter baumannii. *Future Microbiol*. 2016;11(3):335–349.
29. Bose S, Ghosh AK. Understanding of quorum-sensing: a possible solution for drug resistance in bacteria. *Int J Curr Microbiol App Sci*. 2016;5(2):540–546.
30. Abraham W-R. Going beyond the control of quorum-sensing to combat biofilm infections. *Antibiotics (Basel)*. 2016;5(1):3.
31. Antunes LC, Imperi F, Towner KJ, Visca P. Genome-assisted identification of putative iron-utilization genes in Acinetobacter baumannii and their distribution among a genotypically diverse collection of clinical isolates. *Res Microbiol*. 2011;162(3):279–284.
32. Ferreira D, Seca AM, Diana C, Silva AM. Targeting human pathogenic bacteria by siderophores: a proteomics review. *J Proteomics*. 2016;145:153–166.
33. Zarrilli R. Acinetobacter baumannii virulence determinants involved in biofilm growth and adherence to host epithelial cells. *Virulence*. 2016;1–2.
34. Fleming A. Penicillin Nobel Lecture. December 11, 1945.
35. Khan MF, Aziz F. Antibiotic resistance: preparation for post-antibiotic era. *EC Microbiology*. 2016;3:409–411.
36. Landecker H. Antibiotic resistance and the biology of history. *Body Soc*. 2016;22(4):19–52.
37. Bathoorn E, Tsioutis C, da Silva Voorham J, et al. Emergence of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close call. *J Antimicrob Chemother*. 2016;71(5):1207–1212.
38. Provasi Cardoso J, Cayó R, Girardello R, Gales AC. Diversity of mechanisms conferring resistance to β -lactams among OXA-23-producing Acinetobacter baumannii clones. *Diagn Microbiol Infect Dis*. 2016;85(1):90–97.
39. Manchanda V, Sanchaita S, Singh NP. Multidrug resistant acinetobacter. *J Glob Infect Dis*. 2010;2(3):291–304.
40. Valencia R, Arroyo LA, Conde M, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. *Infect Control Hosp Epidemiol*. 2009;30(03):257–263.
41. Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. *Int J Antimicrob Agents*. 2016;47(4):317–323.
42. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. *Lancet Infect Dis*. 2008;8(12):751–762.
43. Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. *J Hosp Med*. 2016;11(1):21–26.
44. Tal-Jasper R, Katz DE, Amrami N, et al. Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections. *Antimicrob Agents Chemother*. 2016;60(5):3127–3131.
45. Thi Khanh Nhu N, Riordan DW, Do Hoang Nhu T, et al. The induction and identification of novel Colistin resistance mutations in Acinetobacter baumannii and their implications. *Sci Rep*. 2016;6:28291.
46. Koksai I, Kaya S, Gencalioglu E, Yilmaz G. Evaluation of risk factors for intravenous colistin use-related nephrotoxicity. *Oman Med J*. 2016;31(4):318–321.
47. Trifi A, Abdellatif S, Daly F, et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series. *Chemotherapy*. 2016;61(4):190–196.
48. Ozkan G, Ulusoy S, Orem A, et al. How does colistin-induced nephropathy develop and can it be treated? *Antimicrob Agents Chemother*. 2013;57(8):3463–3469.
49. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Lakhal SB. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. *Ann Intensive Care*. 2016;6(1):1.
50. Ziaka M, Makris D, Markantonis S, Zakynthinos E. Safety of prolonged intraventricular administration of olistin methanesulphonate. *J Neuroinfect Dis*. 2016;7:207.
51. Myint T, Evans ME, Burgess DR, Greenberg RN. Respiratory muscle paralysis associated with colistin, polymyxin B, and muscle relaxants drugs: a case report. *J Investig Med High Impact Case Rep*. 2016;4(1):2324709616638362.

52. Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant *Acinetobacter baumannii* in an in vitro pharmacokinetic/pharmacodynamic model. *Antimicrob Agents Chemother*. 2013;57(8):3738–3745.
53. Silva A, Sousa AM, Alves D, Lourenço A, Pereira MO. Heteroresistance to colistin in *Klebsiella pneumoniae* is triggered by small colony variants sub-populations within biofilms. *Pathog Dis*. 2016;74(5):ftw036.
54. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against *Acinetobacter baumannii* clinical isolates. *J Antimicrob Chemother*. 2007;59(3):473–477.
55. Simsek F, Gedik H, Yildirmak M, et al. Colistin against colistin-only-susceptible *Acinetobacter baumannii*-related infections: monotherapy or combination therapy? *Indian J Med Microbiol*. 2012;30(4):448.
56. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant *Acinetobacter baumannii*. A multicentre, randomised, clinical trial. *Clin Infect Dis*. 2013;57(3):349–358.
57. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of *Acinetobacter baumannii*: clinical reports, mechanisms and antimicrobial strategies. *J Antimicrob Chemother*. 2012;67(7):1607–1615.
58. Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. *J Antimicrob Chemother*. 2017;72(1):29–39.
59. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant *Acinetobacter baumannii* infections. *J Antimicrob Chemother*. 2008;61(2):417–420.
60. Hong DJ, Kim JO, Lee H, et al. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant *Acinetobacter baumannii* clinical isolates. *Diagn Microbiol Infect Dis*. 2016;86(2):184–189.
61. Poulikakos P, Tansarli G, Falagas M. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant *Acinetobacter* infections: a systematic review. *Eur J Clin Microbiol Infect Dis*. 2014;33(10):1675–1685.
62. Yang Y-S, Lee Y, Tseng K-C, et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2016;60(7):4045–4054.
63. Fan B, Guan J, Wang X, Cong Y. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant *Acinetobacter baumannii* in a murine thigh-infection model. *PLoS One*. 2016;11(6):e0157757.
64. Nepka M, Perivolioti E, Kraniotaki E, Politi L, Tsakris A, Pournaras S. In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant *Acinetobacter baumannii* Clinical Isolates. *Antimicrob Agents Chemother*. 2016;60(11):6903–6906.
65. Hejnar P, Kolár M, Hájek V. Characteristics of *Acinetobacter* strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. *Acta Univ Palacki Olomuc Fac Med*. 1999;142:73–77.
66. Oikonomou O, Sarrou S, Papagiannitsis CC, et al. Rapid dissemination of colistin and carbapenem resistant *Acinetobacter baumannii* in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. *BMC Infect Dis*. 2015;15(1):1–6.
67. Gupta M, Lakhina K, Kamath A, et al. Colistin-resistant *Acinetobacter baumannii* ventilator-associated pneumonia in a tertiary care hospital: an evolving threat. *J Hosp Infect*. 2016;94(1):72–73.
68. Stein GE, Babinchak T. Tigecycline: an update. *Diagn Microbiol Infect Dis*. 2013;75(4):331–336.
69. Cunha BA, McDermott B, Nausheen S. Single Daily high-dose tigecycline therapy of a multidrug-resistant (MDR) *Klebsiella pneumoniae* and *Enterobacter aerogenes* nosocomial urinary tract infection. *J Chemother*. 2007;19(6):753–754.
70. Zhang Y-Y, Zhou L, Zhu D-M, et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. *Diagn Microbiol Infect Dis*. 50(4):267–281.
71. Stefani S, Dowzicky JM. Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). *Pharmaceuticals*. 2016;9(4):74.
72. Pournaras S, Koumaki V, Gennimata V, Kouskouni E, Tsakris A. In vitro activity of tigecycline against *Acinetobacter baumannii*: global epidemiology and resistance mechanisms. In: Donelli G, editor. *Advances in Microbiology, Infectious Diseases and Public Health*. Volume 1. Cham: Springer International Publishing; 2016:1–14.
73. Grandesso S, Sapino B, Amici G, Mazzucato S, Solinas M, Gion M. Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR *Acinetobacter baumannii*. *New Microbiol*. 2014;37(4):503–508.
74. Castro AL, Gutierrez GB, Ovalle V, Cortés J, Alvarez C. Comparing in vitro activity of tigecycline by using the disc diffusion test, the manual microdilution method, and the VITEK 2 automated system. *Rev Argent Microbiol*. 2010;42:208–211.
75. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. *Diagn Microbiol Infect Dis*. 2005;52(3):181–186.
76. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother*. 2007;59(4):772–774.
77. Martínez-Gutián M, Vázquez-Ucha JC, Odingo J, et al. Synergy between Colistin and the signal peptidase (SPase) inhibitor MD3 is dependent on the mechanism of colistin resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2016: AAC. 00510-00516.
78. Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev*. 2010;74(3):417–433.
79. Eliopoulos GM, Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis*. 2008;46(8):1254–1263.
80. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2007;51(10):3471–3484.
81. Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β -lactams in peril! *Curr Opin Microbiol*. 2005;8(5):518–524.
82. Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of bla_{OXA-23} with bla_{NDM-1} and armA in clinical isolates of *Acinetobacter baumannii* from India. *J Antimicrob Chemother*. 2010;65(10):2253–2254.
83. Morán-Barrio J, Cameranesi MM, Relling V, Limansky AS, Brambilla L, Viale AM. The *Acinetobacter* outer membrane contains multiple specific channels for carbapenem β -lactams as revealed by kinetic characterization analyses of imipenem permeation into *Acinetobacter baylyi* cells. *Antimicrob Agents Chemother*. 2017;61(3).
84. Buckner MM, Blair JM, La Ragione RM, et al. Beyond antimicrobial resistance: evidence for a distinct role of the AcrD efflux pump in salmonella biology. *mBio*. 2016;7(6):e01916.
85. Yoon E-J, Balloy V, Fiette L, Chignard M, Courvalin P, Grillot-Courvalin C. Contribution of the Ade resistance-nodulation-cell division-type efflux pumps to fitness and pathogenesis of *Acinetobacter baumannii*. *mBio*. 2016;7(3):e00697-16.
86. Lytvynenko I, Brill S, Oswald C, Pos KM. Molecular basis of poly-specificity of the small multidrug resistance efflux pump AbeS from *Acinetobacter baumannii*. *J Mol Biol*. 2016;428(3):644–657.
87. Li L, Hassan KA, Brown MH, Paulsen IT. Rapid multiplexed phenotypic screening identifies drug resistance functions for three novel efflux pumps in *Acinetobacter baumannii*. *J Antimicrob Chemother*. 2016;71(5):1223–1232.
88. Shrestha S, Tada T, Shrestha B, et al. Emergence of aminoglycoside resistance due to armA methylase in multi-drug resistant *Acinetobacter baumannii* isolates in a University Hospital in Nepal. *J Nepal Health Res Counc*. 2016;14(33):72.

89. Ugolotti E, Di Marco E, Bandettini R, Tripodi G, Blassoni R. The whole genome sequencing of *Acinetobacter-calcoaceticus-baumannii* complex strains involved in suspected outbreak in an Intensive Care Unit of a pediatric hospital. *J Hosp Adm*. 2016;5(6):81.
90. Charrier C, Salisbury A-M, Savage VJ, et al. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases. *J Antimicrob Chemother*. 2016;71(10):2831–2839.
91. Yang H, Hu L, Liu Y, Ye Y, Li J. Detection of the plasmid-mediated quinolone resistance determinants in clinical isolates of *Acinetobacter baumannii* in China. *J Chemother*. 2016/09/02 2016;28(5):443–445.
92. Ling B-D, Zhang L, Li X-Z. Antimicrobial resistance and drug efflux pumps in acinetobacter. In: *Efflux-Mediated Antimicrobial Resistance in Bacteria*. Li XZ, Elkins CA, Zgurskaya HI, editors. Springer International Publishing: Springer; 2016:329–358.
93. Bojkovic J, Richie DL, Six DA, et al. Characterization of an *Acinetobacter baumannii* lptD deletion strain: permeability defects and response to inhibition of lipopolysaccharide and fatty acid biosynthesis. *J Bacteriol*. 2016;198(4):731–741.
94. Choi HJ, Kil MC, Choi J-Y, et al. Characterisation of successive *Acinetobacter baumannii* isolates from a deceased haemophagocytic lymphohistiocytosis patient. *Int J Antimicrob Agents*. 2017;49(1):102–106.
95. Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis*. 2016;16(2):161–168.
96. McGann P, Snesrud E, Maybank R, et al. *Escherichia coli* Harboring mcr-1 and blaCTX-M on a Novel IncF Plasmid: first report of mcr-1 in the USA. *Antimicrob Agents Chemother*. 2016;60(7):4420–4421.
97. Ahmed SS, Alp E, Hopman J, Voss A. Global epidemiology on colistin resistant *Acinetobacter baumannii*. *Eur J Clin Microbiol Infect Dis*. 2016;35(9):1469–1468.
98. Schmelcher M, Loessner MJ. Bacteriophage endolysins: applications for food safety. *Curr Opin Biotechnol*. 2016;37:76–87.
99. Lin N-T, Chiou P-Y, Chang K-C, Chen L-K, Lai M-J. Isolation and characterization of ϕ AB2: a novel bacteriophage of *Acinetobacter baumannii*. *Res Microbiol*. 2010;161(4):308–314.
100. García-Quintanilla M, Pulido MR, López-Rojas R, Pachón J, McConnell MJ. Emerging therapies for multidrug resistant *Acinetobacter baumannii*. *Trends Microbiol*. 2013;21(3):157–163.
101. Mohamed MF, Brezden A, Mohammad H, Chmielewski J, Seleem MN. A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and antibiofilm activity against multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Sci Rep*. 2017;7:6953.
102. Luo G, Spellberg B, Gebremariam T, et al. Combination therapy with iron chelation and vancomycin in treating murine staphylococemia. *Eur J Clin Microbiol Infect Dis*. 2014;33(5):845–851.
103. Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics—a pipeline portfolio review. *Lancet Infect Dis*. 2016;16(2):239–251.
104. Bashir T, Ahmed A. Colistin Resistance among Gram Negative Organisms; an Evolving Problem from Tertiary Care Hospital, Pakistan 2014. *American Journal of Microbiology*. 2016.
105. Qadeer A, Akhtar A, Ain QU, et al. Antibigram of Medical Intensive Care Unit at Tertiary Care Hospital Setting of Pakistan. *Cureus*. 2016;8(9):809.
106. Gupta M, Lakhina K, Kamath A, et al. Colistin-resistant *Acinetobacter baumannii* ventilator-associated pneumonia in a tertiary care hospital: an evolving threat. *Journal of Hospital Infection*. 2016;94(1):72–73.
107. Pawar SK, Karande GS, Shinde RV, Pawar VS. Emergence of Colistin Resistant Gram Negative Bacilli, in a Tertiary Care Rural Hospital from Western India. *Indian Journal of Microbiology Research*. 2016;3(3):308–313.
108. Am, Kaur e, Gill AK, et al. Prevalence and Antibigram of *Acinetobacter* spp. Isolated from Various Clinical Samples in a Tertiary Care Hospital, Bathinda. *IJHSR*. 2016;6(6):83–89.
109. Samawi A, Saad M, Khan FY, et al. *Acinetobacter* Infections among Adult Patients in Qatar: A 2-Year Hospital-Based Study. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2016;2016.
110. Maraki S, Mantadakis E, Mavromanolaki VE, Kofteridis DP, Samonis G. A 5-year Surveillance Study on Antimicrobial Resistance of *Acinetobacter baumannii* Clinical Isolates from a Tertiary Greek Hospital. *Infect Chemother*. 2016;48(3):190–198.
111. Al-Samaree MY, Al-Khafaji ZM. Antibigram of *Acinetobacter baumannii* isolated from Baghdad Hospitals. *Int. J. Adv. Res. Biol. Sci*. 2016;3(4):238–242.
112. Alaei N, Aziemzadeh M, Bahador A. Antimicrobial resistance profiles and genetic elements involved in carbapenem resistance in *Acinetobacter baumannii* isolates from a referral hospital in Southern Iran. *Journal of Global Antimicrobial Resistance*. 2016;5:75–79.
113. El-Shazly S, Dashti A, Vali L, Bolaris M, Ibrahim AS. Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of *Acinetobacter baumannii*. *International Journal of Infectious Diseases*. 2015;41:42–49.
114. Maspi H, Hosseini HM, Amin M, Fooladi AAI. High prevalence of extensively drug-resistant and metallo beta-lactamase-producing clinical *Acinetobacter baumannii* in Iran. *Microbial Pathogenesis*. 2016;98:155–159.
115. Ambrosi C, Aleandri M, Giordano A, et al. Molecular characterisation of extensively drug-resistant *Acinetobacter baumannii*: First report of a new sequence type in Italy. *Journal of Global Antimicrobial Resistance*. 2016;7:154–156.
116. Chang K-C, Lin M-F, Lin N-T, et al. Clonal spread of multidrug-resistant *Acinetobacter baumannii* in eastern Taiwan. *Journal of Microbiology, Immunology and Infection*. 2012;45(1):37–42.
117. Rossi F, Girardello R, Cury AP, Gioia TSRD, Almeida Jr JNd, Duarte AJdS. Emergence of colistin resistance in the largest university hospital complex of São Paulo, Brazil, over five years. *The Brazilian Journal of Infectious Diseases*. 2017;21(1):98–101.
118. Batarseh A, Al-Sarhan A, Maayteh M, Al-Khatirei S, Alarmouti M. Antibigram of multidrug resistant *Acinetobacter baumannii* isolated from clinical specimens at King Hussein Medical Centre, Jordan: a retrospective analysis. *Eastern Mediterranean Health Journal*. 2016;21(11):828.
119. Qureshi ZA, Hittle LE, O'Hara JA, et al. Colistin-resistant *Acinetobacter baumannii*: beyond carbapenem resistance. *Clinical infectious diseases*. 2015;60(9):1295–1303.
120. Tojo M, Mawatari M, Hayakawa K, et al. Multidrug-resistant *Acinetobacter baumannii* isolated from a traveler returned from Brunei. *Journal of Infection and Chemotherapy*. 2015;21(3):212–214.
121. Baadani AM, Thawadi SI, El-Khizzi NA, Omrani AS. Prevalence of colistin and tigecycline resistance in *Acinetobacter baumannii* clinical isolates from 2 hospitals in Riyadh Region over a 2-year period. *Saudi medical journal*. 2013;34(3):248–253.
122. Cikman A, Gulhan B, Aydin M, et al. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant *Acinetobacter baumannii* Strains Isolated from Patients with Ventilator-Associated Pneumonia. *International journal of medical sciences*. 2015;12(9):695.
123. Castanheira M, Mendes RE, Jones RN. Update on *Acinetobacter* Species: Mechanisms of Antimicrobial Resistance and Contemporary In Vitro Activity of Minocycline and Other Treatment Options. *Clinical infectious diseases*. December 1, 2014 2014;59(suppl 6):S367–S373.
124. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of Tigecycline and Colistin Resistance in *Acinetobacter* Species Isolated from Patients in Kuwait Hospitals. *Journal of Chemotherapy*. 2011/02/01 2011;23(1):13–16.
125. Ghasemian R, Ahanjan M, Fatehi E, Shokri M. Prevalence and Antibiotic Resistance Pattern of *Acinetobacter* Isolated from Patients Admitted in ICUs in Mazandaran, Northern Iran. *Global journal of health science*. 2016;8(11):112.
126. Kulah C, Celebi G, Aktas E, Mengeloglu Z, Comert F, Ankarali H. Unexpected Tigecycline Resistance Among *Acinetobacter baumannii* Isolates: High Minor Error Rate by Etest. *Journal of Chemotherapy*. 2009/08/01 2009;21(4):390–395.

127. Liao C-H, Kung H-C, Hsu G-J, et al. In-vitro activity of tigecycline against clinical isolates of *Acinetobacter baumannii* in Taiwan determined by the broth microdilution and disk diffusion methods. *International journal of antimicrobial agents*. 32:S192–S196.
128. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant *Acinetobacter baumannii* isolated from ventilator-associated pneumonia. *International journal of antimicrobial agents*. 32(1):29–32.
129. Behera B, Das A, Mathur P, Kapil A, Gadepalli R, Dhawan B. Tigecycline susceptibility report from an Indian tertiary care hospital. *Indian J Med Res*. 2009;129(4):446–450.
130. Kim C-K, Lee Y, Lee H, et al. Prevalence and diversity of carbapenemases among imipenem-nonsusceptible *Acinetobacter*. *Diagn Microbiol Infect Dis*. 2010;68(4):432–438.
131. Van TD, Dinh Q-D, Vu PD, et al. Antibiotic susceptibility and molecular epidemiology of *Acinetobacter calcoaceticus-baumannii* complex strains isolated from a referral hospital in northern Vietnam. *Journal of Global Antimicrobial Resistance*. 2014;2(4):318–321.
132. Garza-González E, Llaca-Díaz JM, Bosques-Padilla FJ, González GM. Prevalence of Multidrug-Resistant Bacteria at a Tertiary-Care Teaching Hospital in Mexico: Special Focus on *Acinetobacter baumannii*. *Chemotherapy*. 2010;56(4):275–279.
133. García C, Juliet L, Fernández V, et al. Multicenter study on the monitoring of in vitro susceptibility to tigecycline in Santiago, Chile]. *Revista chilena de infectología: órgano oficial de la Sociedad Chilena de Infectología*. 2009;26(3):220–226.
134. Rizek C, Ferraz JR, van der Heijden IM, et al. Activity of potential old and new drugs against multidrug-resistant gram-negatives. *Journal of Infection and Chemotherapy*. 21(2):114–117.
135. Ahmed NH, Baba K, Clay C, Lekalakala R, Hoosen AA. In vitro activity of tigecycline against clinical isolates of carbapenem resistant *Acinetobacter baumannii* complex in Pretoria, South Africa. *BMC Research Notes*. 2012;5(1):215.
136. Capone A, D'Arezzo S, Visca P, Petrosillo N. In vitro activity of tigecycline against multidrug-resistant *Acinetobacter baumannii*. *Journal of Antimicrobial Chemotherapy*. 2008;62(2):422–423.
137. Mendes RE, Farrell DJ, Sader HS, Jones RN. Comprehensive assessment of tigecycline activity tested against a worldwide collection of *Acinetobacter* spp. (2005–2009). *Diagnostic Microbiology and Infectious Disease*. 2010;68(3):307–311.
138. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant *Acinetobacter baumannii* isolated from ventilator-associated pneumonia. *International journal of antimicrobial agents*. 2008;32(1):29–32.
139. Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). *Journal of Infection*. 2010;60(6):440–451.
140. Bahador A, Taheri M, Pourakbari B, et al. Emergence of Rifampicin, Tigecycline, and Colistin-Resistant *Acinetobacter baumannii* in Iran; Spreading of MDR Strains of Novel International Clone Variants. *Microbial Drug Resistance*. 2013;19(5):397–406.
141. Hasan B, Perveen K, Olsen B, Zahra R. Emergence of carbapenem-resistant *Acinetobacter baumannii* in hospitals in Pakistan. *Journal of Medical Microbiology*. 2014;63(1):50–55.
142. Al-Agamy MH, Jeannot K, El-Mahdy TS, et al. First Detection of GES-5 Carbapenemase-Producing *Acinetobacter baumannii* Isolate. *Microbial Drug Resistance*. 2017;23(5):556–562.
143. Chmielarczyk A, Pilarczyk-Żurek M, Kamińska W, et al. Molecular Epidemiology and Drug Resistance of *Acinetobacter baumannii* Isolated from Hospitals in Southern Poland: ICU as a Risk Factor for XDR Strains. *Microbial Drug Resistance*. 2016;22(4):328–335.
144. Tsioutis C, Kritsotakis EI, Karageorgos SA, et al. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia in critically ill patients. *International journal of antimicrobial agents*. 2016;48(5):492–497.

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic

resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress